[10] It is worth being exact about what that source says, because the naive reading goes too far in the other direction: the recommendation is to adjust the parenteral copper dose according to serum concentrations and the clinical picture, explicitly not to stop it, since discontinuing copper in cholestatic patients risks producing copper deficiency instead
In this population: Higher waist-to-hip ratio increased risk up to 7.7-fold (especially peri-menopausally) Greater body fat percentage, waist-height ratio, or visceral fat area each increased risk around 4-fold Higher body mass index (BMI) or waist circumference, each, increased risk almost 3-fold Because obesity is associated with significant changes in immunometabolic and hormonal parameters, it seems likely that the strength of these findings will be confirmed in other populations
Eventually, immune disease is where the antigen-presenting cell is able to get the lipid polysaccharide to transpose through the bowel because of the leaky gut stuff
Translating these in vitro findings to an in vivo model, naturally aged male mice from 20-24 months old were treated with FOXO4-DRI
